Patients with EGFR-mutated NSCLC frequently develop brain metastasis [4, 5], which can lead to a higher economic burden, poorer prognosis, and lower QoL compared to metastasis in other sites [6–8]. Here, EGFR is linked to non-small cell lung carcinoma.